Increased Mortality In Rapamune Liver Transplant Study Sparks FDA Alert
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth notified the agency about increased mortality in the sirolimus arm of a comparative study and is seeking a safety update for the immunosuppressant’s labeling, the company said.